Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Video

» Live Case

Saint Luke’s Mid America Heart Institute, Kansas City, MO - Complex Coronary PCI (MVD) and Ischemic Cardiomyopathy

November 17, 2023

Video

» Live Case

NSTEMI Ischemic Cardiomyopathy Severe LVSDRVSD. CTO LAD, Cx and RCA

April 27, 2023

Video

» Topical Discussion

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy Personalizing Treatment to Optimize Outcomes

December 13, 2021

Video

Revascularization Rationale for Stable Ischemic Heart Disease

April 29, 2021

Video

Part 2: The Role of Coronary Revascularization for Stable Ischemic Heart Disease

February 2, 2021

Video

Part 1: The Role of Coronary Revascularization for Stable Ischemic Heart Disease

February 2, 2021

Video

» Interview

REDUCE-IT: Reduction in Total Ischemic Events with Icosapent Ethyl in REDUCE-IT

March 18, 2019

Video

» Interview

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

March 18, 2019

Video

SHDS 2018: Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

July 4, 2018

Advertisement

Saint Luke’s Mid America Heart Institute, Kansas City, MO - Complex Coronary PCI (MVD) and Ischemic Cardiomyopathy

NSTEMI Ischemic Cardiomyopathy Severe LVSDRVSD. CTO LAD, Cx and RCA

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy Personalizing Treatment to Optimize Outcomes

Revascularization Rationale for Stable Ischemic Heart Disease

Part 2: The Role of Coronary Revascularization for Stable Ischemic Heart Disease

Part 1: The Role of Coronary Revascularization for Stable Ischemic Heart Disease

REDUCE-IT: Reduction in Total Ischemic Events with Icosapent Ethyl in REDUCE-IT

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

SHDS 2018: Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content